Lincoln Pharma. (LINCOLN)
Slow GrowerFairStock Score: 50/100 — MIXED
Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹613.4 |
| Market Cap | ₹1,228.62 Cr |
| P/E Ratio | 13.99 |
| ROCE | 17.28% |
| ROE | 12.3% |
| Dividend Yield | 0.3% |
| Profit Growth | 30.93% |
| Debt/Equity | 0.01 |
| Sales Growth | 19.02% |
| Promoter Holding | 49.78% |
| 52-Week Range | ₹440 — ₹770 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹378.34 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹611.45, Lincoln Pharma has a market cap of ₹1,264 Cr and a P/E of 14.39. This is not a classic Graham net-net, but it has traits I admire. The balance sheet is spotless — no debt at all, with a book value of ₹322.75, so a P/B of 1.89 is acceptable for a business earning 13.74% on equity. The ROCE of 17.28% tells me capital is being put to sensible use. With promoters holding 49.78%, their interests are aligned with mine.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer